Novartis Raises Full-Year Earnings Guidance Despite Trial Setbacks
Novartis cited solid sales growth and productivity gains as it raised full-year earnings guidance. Clinical-trial setbacks weighed on third-quarter profit.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Novartis Raises 2026 Core Operating Profit Guidance
Novartis said it expects 2026 core operating profit to rise, citing solid sales growth and productivity gains, despite third-quarter profit pressure from recent clinical-trial setbacks.